Hepatitis Drugs and Vaccines: World Market 2013-2023

Hepatitis Drugs and Vaccines: World Market 2013-2023

Report Details

Your guide to sales outlooks and R&D for hepatitis treatments

Where are hepatitis medicines going? Visiongain's updated report predicts revenues there from 2013 to 2023. It also explains trends in that business and technology - with prospects and opportunities - to help your work.

In that study you gain sales forecasts at overall world market, submarket, product, and national level. See what's happening. Also discover what has most growth potential.

Read on, then, to explore that industry and see what its future market could be worth.

Forecasts to 2023 and other analyses show you commercial potentials

Besides revenue forecasting, our new work shows historical data, growth rates, and market shares. You discover original quantitative and qualitative analysis, seeing business outlooks and research developments (R&D). You also get 77 tables, 66 charts, and an interview.

Is finding data for anti-hepatitis products a challenge? Avoid falling behind. You can now stay ahead in knowledge, benefiting your research, analyses, and decisions. Also save time.

There you investigate the future of hepatitis medicine. You discover what's happening and see where the money lies. Finding that antiviral data just got easier.

Anyhow, the following sections show what you get in our new research and analysis.

Discover prospects for the world market and submarkets

Our new report shows revenue to 2023 for the overall world market. It also shows you individual forecasts of four hepatitis treatment submarkets:
• Oral antivirals
• Interferons
• Vaccines
• Other agents.

How will the hepatitis drugs and vaccines market expand? Which parts will most prosper? There you assess potential for sales and revenue growth.

Also our study discusses what stimulates and restrains that market. That analysis helps you identify potential and find ways for your business to benefit.

You also find revenue predictions for brands.

See forecasts for 10 leading anti-hepatitis products

How will those antiviral brands perform to 2023 at world level? Our study forecasts individual revenues of 10 top products:
• Baraclude
• Zeffix
• Hepsera
• Viread
• Tyzeka
• Engerix-B/Havrix/Twinrix/Fendrix
• Pegasys
• Incivek
• PegIntron
• Victrelis.

There you discover how high sales can go, to 2023, finding products and years with highest predicted growth and revenues. Also you compare competitors. You see what's happening, then, understanding trends, competition, challenges, and opportunities.

Our report also divides its overall world forecast into geographical regions.

What prospects for regions and countries?

Developments worldwide expand the hepatitis products market, especially rising demand for medicines in emerging countries. China, India, Russia, and Brazil underpin revenue growth.

In developed and developing countries, opportunities for pharmaceutical companies will occur from 2013 to 2023. See where and how.

Our analyses show you individual revenue forecasts to 2023 for 11 national markets:
• United States (US)
• Japan
• EU leaders - Germany, France, the UK, Italy, and Spain (EU5)
• BRIC countries - Brazil, Russia, India, and China.

There you discover progress and outlooks. In particular, drug and vaccine launches from 2013 to 2023 will change medical prescribing and the commercial landscape. See how.

Research and development - assess innovation, trends, and possibilities

What about R&D - pipelines for new drugs and vaccines? You assess trends there, including these:
• Cyclophilin inhibition
• Protease inhibition
• All-oral agents
• Agents with potential roles in hep-C/HIV co-infection
• Nucleoside and non-nucleoside polymerase inhibition
• Therapeutic vaccines
• Combination reg
Table of Contents

1. Executive Summary
1.1 Hepatitis Treatments and Vaccines: World Market Overview
1.2 Chapter Breakdown
1.3 Research and Analysis Methods

2. Introduction to Hepatitis and its Treatments
2.1 What is Hepatitis?
2.2 Diagnosing Hepatitis: The Asymptotic Nature of the Disease
2.3 How is Hepatitis Classified?
2.3.1 Hepatitis A
2.3.2 Hepatitis B
2.3.3 Hepatitis C
2.3.4 Hepatitis D
2.3.5 Hepatitis E
2.4 Risk Factors for Hepatitis
2.5 Incidence and Prevalence Patterns in Hepatitis
2.6 Hepatitis: Treatment and Prevention
2.6.1 Antivirals: Inhibiting Viral Replication Reverse Transcriptase Inhibitors Protease Inhibitors
2.6.2 Interferons: Dual Mode of Action Combination Therapy: Treatment with Interferon and Antivirals
2.6.3 Vaccines: The Immunotherapeutic Approach Hepatitis E Vaccine: Raising Hopes for an Overlooked Subtype

3. World Hepatitis Treatments and Vaccines Market, 2013-2023
3.1 The Hepatitis Treatments and Vaccines Market, 2012
3.1.1 The Hepatitis Treatment Market by Indication, 2012
3.2 The Hepatitis Treatments and Vaccines Market: Revenue Forecast, 2013-2023
3.2.1 Rising Awareness and Screening: Expanding Treatment Population
3.2.2 Generic Competition in the Hepatitis B Treatment Market
3.2.3 Biosimilar Interferons: A New Era in Hepatitis Treatment?
3.2.4 Direct-Acting Antivirals (DAAs): A Change in Therapeutic Landscape
3.3 Oral Antivirals Submarket, 2012
3.3.1 DAAs in Hepatitis B
3.3.2 DAAs in Hepatitis C
3.3.3 Oral Antivirals Submarket: Revenue Forecast, 2013-2023
3.3.4 Strong Developmental Pipeline to Drive Market Growth
3.3.5 All-Oral Treatments for Hepatitis C: Improving Tolerability
3.4 Interferons Submarket, 2012
3.4.1 Standard of Care for Hepatitis C
3.4.2 Drawbacks to Interferon Therapy
3.4.3 Declining Revenues 2008-2011
3.4.4 Interferons Submarket: Revenue Forecast, 2013-2023
3.4.5 Next Generation Interferons: A Potential Advance or Lateral Move?
3.5 Hepatitis Vaccines Submarket, 2012
3.5.1 GSK: A Dominant Global Player
3.5.2 Expanding Vaccination Programmes in Emerging Markets
3.5.3 Hepatitis Vaccines Submarket: Revenue Forecast, 2013-2023
3.6 Hepatitis Treatments and Vaccines: Submarket Shares 2012, 2018 and 2023
3.7 Hepatitis Treatment Market: Revenue Forecast by Indication, 2013-2023

4. Leading National Hepatitis Treatments and Vaccines Markets, 2013-2023
4.1 Global Prevalence of Hepatitis, 2012
4.1.1 The Importance of Asia
4.2 Hepatitis Treatments and Vaccines Market: Regional Breakdown, 2012
4.3 Hepatitis Treatments and Vaccines Market: Regional Forecast, 2013-2023
4.4 The US
4.4.1 Population Movement and Hepatitis
4.4.2 Increased Screening towards Target Population
4.4.3 The US: Revenue Forecast, 2013-2023
4.5 Leading EU Markets for Hepatitis Treatments and Vaccines
4.5.1 Regional Prevalence
4.5.2 EU5 Market, 2012
4.5.3 EU5: Revenue Forecasts, 2013-2023
4.5.4 Italy: Revenue Forecast, 2013-2023
4.5.5 Spain: Revenue Forecast, 2013-2023
4.5.6 Germany: Revenue Forecast, 2013-2023
4.5.7 UK: Revenue Forecast, 2013-2023
4.5.8 France: Revenue Forecast, 2013-2023
4.6 Hepatitis in Asia
4.7 China
4.7.1 Increased Vaccination
4.7.2 Rising Middle Class
4.7.3 Hepatitis C Outbreaks
4.7.4 Domestic Drug and Vaccine Development
4.7.5 China: Revenue Forecast, 2013-2023
4.8 Japan
4.8.1 Hepatitis B and C in Japan
4.8.2 Japan: Revenue Forecast, 2013-2023
4.9 India
4.9.1 Low Awareness and Vaccination Rates
4.9.2 India: Revenue Forecast, 2013-2023
4.10 Russia
4.10.1 Low Treatment Rate and High Drug Costs Limiting Market
4.10.2 Russia: Revenue Forecast, 2013-2023
4.11 Brazil
4.11.1Current Disease Prevalence
4.11.2 Brazil: Revenue Forecast, 2013-2023

5. Leading Hepatitis